Findings

What do systematic reviews say?

19 questions · 19 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 36.8%GRADE not reported 0 · 0%Very low 3 · 15.8%Low 9 · 47.4%Moderate 0 · 0%High 0 · 0%

Cromolyn sodium vs placebo

Clinical improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cromolyn sodium vs placebo

Clinical improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Low

Cromolyn sodium vs placebo

Histological improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cromolyn sodium vs placebo

Histological improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 15 participants
Low

Cromolyn sodium vs placebo

Endoscopic improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cromolyn sodium vs placebo

Endoscopic improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cromolyn sodium vs placebo

Withdrawals due to adverse events · active EoE pediatric patients

Cromolyn sodium showed no clear difference in withdrawals due to adverse events at 8 weeks compared with placebo (low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 0.27 [0.01, 5.7]
1 study · 16 participants
Low

Cromolyn sodium vs placebo

Pruritus · patients with chronic kidney disease (CKD) pruritus

1 finding from 1 review

Pharmacological interventions for pruritus in adult palliative care patients 2024 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 100 participants
Very low

Cromolyn sodium vs placebo

Quality of life ‐ not measured · patients with chronic kidney disease (CKD) pruritus

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for pruritus in adult palliative care patients 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cromolyn sodium vs placebo

Patient satisfaction ‐ not measured · patients with chronic kidney disease (CKD) pruritus

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for pruritus in adult palliative care patients 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cromolyn sodium vs placebo

Depression ‐ not measured · patients with chronic kidney disease (CKD) pruritus

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for pruritus in adult palliative care patients 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cromolyn sodium vs placebo

Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus

It is very uncertain whether summary of findings table ‐ Cromolyn sodium changes risk for at least one adverse event per patient compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological interventions for pruritus in adult palliative care patients 2024 · Cochrane Headline outcomes only
RR 1.28 [0.02, 106.52]
2 studies · 122 participants
Very low

Intervention not reported

Mortality or CLD at 28/30 days · preterm infants

The intervention showed no clear difference in mortality or CLD at 28/30 days (low certainty).

1 finding from 1 review

Cromolyn sodium for the prevention of chronic lung disease in preterm infants 2017 · Cochrane Headline outcomes only
RR 1.05 [0.73, 1.52]
2 studies · 64 participants
Low

Intervention not reported

Mortality to 28 days · preterm infants

It is very uncertain whether the intervention changes mortality to 28 days (very low certainty).

1 finding from 1 review

Cromolyn sodium for the prevention of chronic lung disease in preterm infants 2017 · Cochrane Headline outcomes only
RR 1.31 [0.52, 3.29]
2 studies · 64 participants
Very low

Intervention not reported

CLD at 28 days · preterm infants

The intervention showed no clear difference in CLD at 28 days (low certainty).

1 finding from 1 review

Cromolyn sodium for the prevention of chronic lung disease in preterm infants 2017 · Cochrane Headline outcomes only
RR 0.93 [0.53, 1.64]
2 studies · 64 participants
Low

Intervention not reported

CLD at 36 weeks' PMA · preterm infants

The intervention showed no clear difference in CLD at 36 weeks' PMA (low certainty).

1 finding from 1 review

Cromolyn sodium for the prevention of chronic lung disease in preterm infants 2017 · Cochrane Headline outcomes only
RR 1.25 [0.43, 3.63]
1 study · 26 participants
Low

Intervention not reported

CLD among survivors to 28 days · preterm infants

The intervention showed no clear difference in CLD among survivors to 28 days (low certainty).

1 finding from 1 review

Cromolyn sodium for the prevention of chronic lung disease in preterm infants 2017 · Cochrane Headline outcomes only
RR 0.97 [0.58, 1.63]
2 studies · 50 participants
Low

Intervention not reported

CLD among survivors to 36 weeks' PMA · preterm infants

The intervention showed no clear difference in CLD among survivors to 36 weeks' PMA (low certainty).

1 finding from 1 review

Cromolyn sodium for the prevention of chronic lung disease in preterm infants 2017 · Cochrane Headline outcomes only
RR 1.04 [0.38, 2.87]
1 study · 22 participants
Low

Intervention not reported

Days on mechanical ventilation · preterm infants

1 finding from 1 review

Cromolyn sodium for the prevention of chronic lung disease in preterm infants 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Low